Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.02.22	Year-end Report - January-December 2021 (GlobeNewswire)
21.02.22	The rights issue is registered and the trading in Paid Subscription Shares ceases (GlobeNewswire)
07.02.22	Karolinska Development AB announces definitive outcome in rights issue (GlobeNewswire)
04.02.22	Karolinska Development AB announces preliminary outcome in rights issue (GlobeNewswire)
03.02.22	Karolinska Development's portfolio company AnaCardio raises SEK 33 million to progress clinical development of a novel therapy for heart failure (GlobeNewswire)
14.01.22	Karolinska Development AB publishes prospectus including previously unpublished financial information due to upcoming rights issue, and invites to investor presentations (GlobeNewswire)
12.01.22	Karolinska Development’s Extraordinary General Meeting 2022 (GlobeNewswire)
11.01.22	Karolinska Development's portfolio company Umecrine Cognition presents preclinical data showing that golexanolone reduces neuroinflammation and counteracts motor symptoms (GlobeNewswire)
11.01.22	Karolinska Development's portfolio company Svenska Vaccinfabriken appoints Richard Bethell as new CEO (GlobeNewswire)
13.12.21	Organon’s acquisition of Karolinska Development's portfolio company Forendo Pharma has been successfully completed (GlobeNewswire)
10.12.21	Notice of Extraordinary General Meeting in Karolinska Development AB (publ) (GlobeNewswire)
10.12.21	Karolinska Development AB (publ) proposes a rights issue of approximately SEK 491 million, and publishes a proposal for a new Board member (GlobeNewswire)
01.12.21	Karolinska Development’s portfolio company Modus Therapeutics initiates Phase 1b trial of its drug candidate sevuparin (GlobeNewswire)
18.11.21	Interim Report - January-September 2021 (GlobeNewswire)
11.11.21	Organon acquires Karolinska Development’s portfolio company Forendo Pharma at a total purchase price of USD 945 million provided fulfilment of all milestones (GlobeNewswire)
09.11.21	Karolinska Development’s portfolio company receives approval to initiate a clinical Phase 1b trial with sevuparin in the Netherlands (GlobeNewswire)
03.11.21	Karolinska Development’s portfolio company Umecrine Cognition presents new data supporting the development of golexanolone as a treatment of primary biliary cholangitis (GlobeNewswire)
27.10.21	Karolinska Development’s portfolio company Dilafor recruits first patient to Phase 2a study of tafoxiparin in women diagnosed with preeclampsia (GlobeNewswire)
25.10.21	Karolinska Development’s portfolio company AnaCardio strengthens its organization to facilitate clinical trial of the drug candidate AC01 in heart failure (GlobeNewswire)
19.10.21	Karolinska Development's portfolio company Umecrine Cognition to collaborate with University College London to increase insights about golexanolone (GlobeNewswire)
04.10.21	Karolinska Development's portfolio company OssDsign receives expanded FDA market clearance for OssDsign Cranial PSI (GlobeNewswire)
09.09.21	Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst (GlobeNewswire)
19.08.21	Interim Report - January-June 2021 (GlobeNewswire)
16.08.21	Karolinska Development's portfolio company OssDsign launches the synthetic bone graft OssDsign Catalyst on the U.S. market (GlobeNewswire)
12.08.21	Karolinska Development's portfolio company Aprea Therapeutics announces that FDA has issued a clinical hold on lymphoid malignancy program (GlobeNewswire)
22.07.21	Karolinska Development’s portfolio company Aprea Therapeutics announces positive Phase 2 results for eprenetapopt (GlobeNewswire)
15.07.21	Karolinska Development’s portfolio company Modus Therapeutics raises SEK 33 million through an oversubscribed issue and now prepares for listing (GlobeNewswire)
14.07.21	Karolinska Development’s portfolio company Umecrine Cognition raises capital through a successful share issue (GlobeNewswire)
07.07.21	Karolinska Development’s portfolio company Promimic receives market clearance for HAnano Surface in orthopedic oncology in collaboration with Onkos Surgical (GlobeNewswire)
07.07.21	Karolinska Development sells its holding in Lipidor AB and receives a net of SEK 4 million (GlobeNewswire)
17.06.21	Karolinska Development expands its portfolio through new investment in AnaCardio (GlobeNewswire)
17.06.21	Karolinska Development increases book value of Dilafor that is indirectly owned via KDev Investments AB by SEK 450 million (GlobeNewswire)
17.06.21	Karolinska Development’s portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia (GlobeNewswire)
15.06.21	Karolinska Development’s portfolio company Modus Therapeutics and Imperial College London to conduct clinical study of sevuparin in severe malaria (GlobeNewswire)
11.06.21	Karolinska Development’s portfolio company Promimic evaluates the possibility of a listing on Nasdaq First North Growth Market (GlobeNewswire)
10.06.21	Karolinska Development’s portfolio company Biosergen raises SEK 50 million through a successful unit offering and prepares for IPO (GlobeNewswire)
01.06.21	Karolinska Development’s portfolio company Dilafor presents positive results from a phase 2b study of tafoxiparin (GlobeNewswire)
21.05.21	Karolinska Development's portfolio company Umecrine Cognition initiates preparations for listing on Nasdaq First North Growth Market (GlobeNewswire)
12.05.21	Karolinska Development’s portfolio company OssDsign raises SEK 270 million through an oversubscribed rights issue (GlobeNewswire)
05.05.21	Karolinska Development’s Annual General Meeting 2021 (GlobeNewswire)
29.04.21	Interim Report - January-March 2021 (GlobeNewswire)
22.04.21	Karolinska Development's portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal (GlobeNewswire)
09.04.21	Karolinska Development’s portfolio company Aprea Therapeutics receives orphan drug designation for eprenetapopt in AML (GlobeNewswire)
06.04.21	Karolinska Development’s portfolio company Dilafor completes patient inclusion to Phase 2b trial of its drug candidate tafoxiparin (GlobeNewswire)
30.03.21	Notice of Annual General Meeting in Karolinska Development AB (publ) (GlobeNewswire)
25.03.21	Karolinska Development Annual Report 2020 published (GlobeNewswire)
15.03.21	Karolinska Development's portfolio company Modus Therapeutics initiates preparations for listing on Nasdaq First North Growth Market (GlobeNewswire)
10.03.21	Karolinska Development's portfolio company Modus Therapeutics prepares clinical development program of sevuparin in sepsis/septic shock (GlobeNewswire)
03.03.21	Karolinska Development’s portfolio company Forendo Pharma advances FOR-6219 to Phase 2 based on positive Phase 1 data (GlobeNewswire)
02.03.21	Karolinska Development’s portfolio company OssDsign announces a fully guaranteed rights issue and launches new corporate strategy (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Sonova Hldg	262.10	3.39 %	K V
Lonza Grp	584.80	2.38 %	K V
Logitech Intl	66.76	1.71 %	K V
Part Grp Hldg	1’114.00	1.41 %	K V
Swisscom	544.00	0.74 %	K V
ABB	45.07	0.04 %	K V
Novartis	90.91	-0.22 %	K V
Zurich Insur Gr	581.00	-0.34 %	K V
Roche Hldg G	257.60	-0.88 %	K V
Kuehne+Nagel Int	177.85	-3.24 %	K V

Karolinska Development AB Aktie VALOR 3662575 / ISIN SE0002190926

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten